Multi-Dose Antibiotic — Competitive Intelligence Brief

Multi-Dose Antibiotic (Multi-Dose Antibiotic) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination. Area: Infectious Disease.

marketed Antibiotic combination Infectious Disease Small molecule

Target snapshot

Multi-Dose Antibiotic (Multi-Dose Antibiotic) — The Cleveland Clinic. A multi-dose antibiotic formulation that delivers multiple antimicrobial agents to treat bacterial infections.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Multi-Dose Antibiotic TARGET	Multi-Dose Antibiotic	The Cleveland Clinic	marketed	Antibiotic combination
Mupirocin + Chlorhexidin	Mupirocin + Chlorhexidin	B. Braun Medical SA	marketed	Topical antibiotic combination	Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane (chlorhexidine)
Intranasal Mupirocin and Topical Chlorhexidine	Intranasal Mupirocin and Topical Chlorhexidine	University of Maryland, Baltimore	marketed	Topical antibiotic combination	Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane and proteins (chlorhexidine)
Ceftazidime-avibactam + Colistin/Polymyxin B	Ceftazidime-avibactam + Colistin/Polymyxin B	National University of Singapore	marketed	Beta-lactam/beta-lactamase inhibitor + polymyxin antibiotic combination	Bacterial peptidoglycan cross-linking enzymes (PBPs); beta-lactamases; bacterial cell membrane lipopolysaccharide and phospholipids
Lansoprazole/Amoxicillin/Clarithromycin	Lansoprazole/Amoxicillin/Clarithromycin	HK inno.N Corporation	marketed	Proton pump inhibitor + antibiotic combination	H+ ATPase (lansoprazole); bacterial cell wall (amoxicillin); bacterial ribosome (clarithromycin)
clindamycin 1% / benzoyl peroxide 5% tube	clindamycin 1% / benzoyl peroxide 5% tube	Sanofi	marketed	Topical antibiotic combination	Bacterial 50S ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
omeprazole plus amoxicillin	omeprazole plus amoxicillin	National Taiwan University Hospital	marketed	Proton pump inhibitor + beta-lactam antibiotic combination	Proton pump (H+/K+-ATPase) and bacterial cell wall (penicillin-binding proteins)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination class)

1. Michael E. DeBakey VA Medical Center · 2 drugs in this class
2. University of South Florida · 2 drugs in this class
3. Halmstad County Hospital · 1 drug in this class
4. Hospital General Universitario Elche · 1 drug in this class
5. Hospital de Clinicas de Porto Alegre · 1 drug in this class
6. McMaster University · 1 drug in this class
7. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
8. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
9. The Cleveland Clinic · 1 drug in this class
10. The Forsyth Institute · 1 drug in this class